The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
In vitro and in vivo characterization of PF‐04418948, a novel, potent and selective prostaglandin EP2receptor antagonist
Open accessAbstract
BACKGROUND AND PURPOSE Studies of the role of the prostaglandin EP 2 receptor) have been limited by the availability of potent and selective antagonist tools. Here we describe the in vitro/in vivo pharmacological characterization of a novel EP 2 receptor antagonist, PF‐04418948 (1‐(4‐fluorobenzoyl)‐3‐{[(6‐methoxy‐2‐naphthyl)oxy]methyl} azetidine‐3‐carboxylic acid). EXPERIMENTAL APPROACH Functional antagonist potency was assessed in cell‐based systems expressing human EP 2 receptors and native tissue preparations from human, dog and mouse. The selectivity of PF‐04418948 was assessed against related receptors and a panel of GPCRs, ion channels and enzymes. The ability of PF‐04418948 to pharmacologically block EP 2 receptor function in vivo was tested in rats. KEY RESULTS PF‐04418948 inhibited prostaglandin E 2(PGE 2)‐induced increase in cAMP in cells expressing EP 2 receptors with a functional K B value of 1.8 nM. In human myometrium, PF‐04418948 produced a parallel, rightward shift of the butaprost‐induced inhibition of the contractions induced by electrical field stimulation with an apparent K B of 5.4 nM. In dog bronchiole and mouse trachea, PF‐04418948 produced parallel rightward shifts of the PGE 2‐induced relaxation curve with a K B of 2.5 nM and an apparent K B of 1.3 nM respectively. Reversal of the PGE 2‐induced relaxation in the mouse trachea by PF‐04418948 produced an IC 50 value of 2.7 nM. Given orally, PF‐04418948 attenuated the butaprost‐induced cutaneous blood flow response in rats. PF‐04418948 was selective for EP 2 receptors over homologous and unrelated receptors, enzymes and channels. CONCLUSIONS AND IMPLICATIONS PF‐04418948 is an orally active, potent and selective surmountable EP 2 receptor antagonist that should aid further elaboration of EP 2 receptor function. LINKED ARTICLE This article is commented on by Birrell and Nials, pp. 1845–1846 of this issue. To view this commentary visit http://dx.doi.org/10.1111/j.1476‐5381.2011.01494.x
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
Cited by
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Restoring metabolism of myeloid cells reverses cognitive decline in ageing
Minhas, P. S., Latif-Hernandez, A., McReynolds, M. R., Durairaj, A. S., Wang, Q., Rubin, A., Joshi, A. U., He, J. Q., Gauba, E., Liu, L., et al. (2021) · Nature · doi:10.1038/s41586-020-03160-0 · Cited by 526
Big opportunities for small molecules in immuno-oncology
Adams, J. L., Smothers, J., Srinivasan, R., & Hoos, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4596 · Cited by 471
Opportunities for Small Molecules in Cancer Immunotherapy
van der Zanden, S. Y., Luimstra, J. J., Neefjes, J., Borst, J., & Ovaa, H. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.04.004 · Cited by 119
Rieg, A. D., Suleiman, S., Anker, C., Verjans, E., Rossaint, R., Uhlig, S., & Martin, C. (2018) · Respiratory Research · doi:10.1186/s12931-018-0829-5 · Cited by 59
Metadata
- Authors
- af Forselles, K., Root, J., Clarke, T., Davey, D., Aughton, K., Dack, K., & Pullen, N.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2011-11-15
- Volume
- 164
- Issue
- 7
- Pages
- 1847-1856
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1738485982
- Cited by
- 161
- References
- 1
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In vitro and in vivo characterization of PF‐04418948, a novel, potent and selective prostaglandin EP2receptor antagonist. https://app.cochat.ai/papers/10.1111/j.1476-5381.2011.01495.x
- The paper
- af Forselles, K., Root, J., Clarke, T., Davey, D., Aughton, K., Dack, K., & Pullen, N. (2011). In vitro and in vivo characterization of PF‐04418948, a novel, potent and selective prostaglandin EP2receptor antagonist. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2011.01495.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.